摘要
目的分析在治疗儿童咳嗽变异性哮喘(CVA)中,孟鲁司特钠联合盐酸西替利嗪的治疗效果。方法研究筛选2021年6月至2023年6月郑州市金水区总医院收治的72例CVA患儿,遵循治疗方式的不同分两组,各36例,对照组以孟鲁司特钠治疗,观察组在对照组的基础上联合盐酸西替利嗪治疗,比较两组患儿治疗效果、血清神经营养素-3(NT-3)、嗜酸粒细胞(EOS)、免疫球蛋白E(IgE)、免疫球蛋白(IgA)水平以及肺功能指标[最大呼气峰流速(PEF)、第1秒用力呼气量(FEV_(1)),并计算1秒用力呼气容积占用力肺活量百分比(FEV_(1)/FVC)]、症状缓解时间和住院时间。结果观察组治疗效果优于对照组,差异具有统计学意义(P<0.05)。治疗前两组EOS、NT-3水平及血清lgA、lgE水平,差异无统计学意义(P>0.05),治疗后观察组EOS、NT-3、lgE均低于对照组,lgA高于对照组,差异具有统计学意义(P<0.05)。治疗前两组肺功能指标PEF、FEV_(1)、FEV_(1)/FVC差异无统计学意义(P>0.05),治疗后观察组肺功能各指标高于对照组,差异具有统计学意义(P<0.05)。观察组住院时间和症状缓解时间显著短于对照组,差异具有统计学意义(P<0.05)。结论孟鲁司特钠、盐酸西替利嗪联合治疗CVA可提高血清NT-3、EOS水平,调控血清lgA、lgE水平,能缩短症状恢复时间及住院时间,值得应用。
Objective To analyze the therapeutic effect of montelukast sodium combined with cetirizine hydrochloride in the treatment of children with cough variant asthma(CVA).Methods A total of 72 children with CVA treated in Zhengzhou Jinshui District General Hospital from June 2021 to June 2023 were selected for the study.According to different treatment methods,they were divided into two groups,each with 36 cases.The control group was treated with montelukast sodium,and the observation group was treated with cetirizine hydrochloride on the basis of the control group.The treatment effects,serum neurotrophin-3(NT-3),eosinophils(EOS),immunoglobulin E(IgE),immunoglobulin A(IgA)levels,and lung function indicators[peak expiratory flow(PEF),forced expiratory volume in the first second(FEV_(1)),and the percentage of forced expiratory volume in one second to forced vital capacity(FEV_(1)/FVC)],symptom relief time,and hospital stay of the two groups were compared.Results The treatment effect of the observation group was better than that of the control group,with a statistically significant difference(P<0.05).Before treatment,there was no statistically significant difference in EOS,NT-3,serum IgA,and IgE levels between the two groups(P>0.05).After treatment,the EOS,NT-3,and IgE levels of the observation group were lower than those of the control group,and IgA was higher than that of the control group,with statistically significant differences(P<0.05).Before treatment,there was no statistically significant difference in lung function indicators PEF,FEV_(1),and FEV_(1)/FVC between the two groups(P>0.05).After treatment,all lung function indicators of the observation group were higher than those of the control group,with statistically significant differences(P<0.05).The hospital stay and symptom relief time of the observation group were significantly shorter than those of the control group,with statistically significant differences(P<0.05).Conclusion The combined treatment of montelukast sodium and cetirizine hydrochloride for CVA ca
作者
于俊芳
YU Junfang(Department of Pediatrics,Zhengzhou Jinshui District General Hospital,Zhengzhou Henan 450000,China)
出处
《临床研究》
2024年第7期54-57,共4页
Clinical Research
关键词
咳嗽变异性哮喘
肺功能
孟鲁司特钠
盐酸西替利嗪
cough variant asthma
lung function
montelukast sodium
cetirizine hydrochloride
